Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Single treatment of bizaxofusp doubled mOS (14.5 months vs. 7.2 months) irrespective of IL4R expression (high or low) compared to patients treated in the external control arm Survival for bizaxofusp-treated patients increased 370% at Year 1 and increased more than 50% at Year 2 TORONTO and HOUSTON, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines,
Cash runway extended through multiple data readouts and into Q1 of calendar 2025 MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1 portion of the ABILITY-1 Study including 100% and 70% reduction of target lesions in pancreatic and melanoma cancer patients, respectively Four-year follow-up survival results from Phase 2b bizaxofusp (MDNA55) study in patients with recurrent glioblastoma selected for presentation at SNO 2023 on November 17
By David Bautz, PhD TSX:MDNA.TO OTC:MDNAF READ THE FULL MDN.TO RESEARCH REPORT Business Update Update on Phase 1/2 ABILITY Trial On November 6, 2023, Medicenna (TSX:MDNA.TO) (OTC:MDNAF) announced that updated results from the Phase 1/2 ABILITY (A Beta-only IL-2 ImmunoTherapY Study) trial of MDNA11 were presented at SITC. MDNA11 is the company’s albumin-fused, long-acting, IL-2 agonist that
TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that a poster presentation and an oral summary highlighting long-term follow up from the Phase 2b clinical trial of bizaxofusp (formerly known as MDNA55), the Company’s first-in-class IL-4R targeted therapy, will be presented at the Society for Neuro-Oncology (SN
MDNA11 continues to demonstrate encouraging single-agent activity from the dose escalation and evaluation portion of the ABILITY-1 Study including deep ongoing partial responses with 100% reduction of target lesions in one pancreatic and 70% reduction of target lesion in one melanoma cancer patientMDNA11 also showed durable stable disease in 3 melanoma patients for at least 5 months to 18 months with concomitant shrinkage of tumor size following failure with check-point inhibitor therapiesMDNA11
Company’s T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that delivers a masked bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment where it is activated by cancer specific enzymes IL-13Rα2 is overexpressed by some of the most immunologically “cold” tumors with high unmet needs in pancreatic,
The Company’s listing on the Toronto Stock Exchange will not be impactedTORONTO and HOUSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of engineered cytokines, announced today that the Company received a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”), which notified the Company of the delist
New data from the Phase 1 dose-escalation and evaluation portion of the trial will be presented at the Society of Immunotherapy for Cancer (SITC) Annual Meeting on November 4, 2023 Company expects to report initial results from both the monotherapy and combination arms of the Phase 2 dose expansion study in H1 2024 TORONTO and HOUSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company foc
TORONTO and HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, announced poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) to be held in San Diego, CA, from November 1-5th, 2023. The company will present an update from its Phase 1/2 ABILITY Study including anti-tumor activity, safety, pharmacoki
Dr. Gardner brings over 30 years of experience leading clinical development to support innovative oncology programs and translational research at global biopharmaceutical companies and major academic institutionsTORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner, M.D., a